IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

NCT07025889 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: IBI343
DRUG: Sintilimab
DRUG: Oxaliplatin
DRUG: S-1

Sponsor

Ruijin Hospital

Collaborators

[object Object]